adagrasib,Pembrolizumab
mirati,merck
['nsclc', 'sclc']
 i do agree - but it is still encouraging as most of the toxicity from tki post immunotherapy in nsclc happens pretty early. at the same time, those are cases where immunotherapy has been given for quite some time before the tki. lots of considerations but still encouraging.
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Host Official @IASLC Podcast #LCSM #HereWeGo #ITYSL